Product Description
Lesinurad is used in combination with a xanthine oxidase inhibitor to treat hyperuricemia (high levels of uric acid) in people with gout (sudden attacks of redness, swelling, pain, and heat in one or more joints) whose disease is not controlled with their current medication. Lesinurad is in a class of medications called selective uric acid reabsorption inhibitors. It works by helping the kidneys to remove uric acid from the body. (Sourced from: https://medlineplus.gov/druginfo/meds/a616015.html)
Mechanisms of Action: URAT1 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Belgium | Brazil | Colombia | Denmark | Egypt | European Medicines Agency | Germany | Greece | Hungary | Ireland | Italy | Lithuania | New Zealand | Poland | Portugal | Spain | Sweden
Approved Indications: Gout | Gout
Known Adverse Events: Headache | Gastroesophageal Reflux | Influenza, Human
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Kidney Failure, Chronic|Gout
Phase 3: Gout
Phase 1: Healthy Volunteers|Gout
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SATURATES | N/A |
Withdrawn |
Gout |
2023-06-30 |
|
| RDEA594-401 | P4 |
Terminated |
Kidney Failure, Chronic |
2019-02-25 |
|
| Lesinurad in Subjects with Gout abd Moderate Renal Impairment | P4 |
Terminated |
Gout |
2018-12-18 |
|
| RDEA594-504 | P1 |
Completed |
Gout |
2017-10-04 |
22% |